Literature DB >> 10487612

VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.

Y Ohta1, V Shridhar, R K Bright, G P Kalemkerian, W Du, M Carbone, Y Watanabe, H I Pass.   

Abstract

The vascular endothelial growth factor (VEGF) family is a novel regulator of endothelial cell proliferation. We assessed the mRNA expression of VEGF, VEGF type C (VEGF-C) and their receptors together with the microvessel density (VD) and microlymphatic vessel density (LVD) in pursuit of their connection and prognostic value in malignant pleural mesothelioma (MPM). We used four human MPM cell lines, 54 MPM tumours and five normal pleural tissues. Expression levels for receptors and ligands were assessed by semiquantitative reverse transcriptase polymerase chain reaction analysis. Microvessels were highlighted by immunohistochemical staining for factor VIII. The discrimination of lymphatics was performed by enzyme-histochemistry for 5'-nucleotidase after adequate inhibition of non-specific activity. The expression levels of VEGF, VEGF-C and VEGFRs were high in all MPM cell lines. The percentages of tumours with higher expression compared to the mean values of normal pleural tissues were 31.5% (17/54) for VEGF, 66.7% (36/54) for VEGF-C, 20.4% (11/54) for fms-like tyrosine kinase (flt)-1, 42.6% (23/54) for kinase insert domain-containing recepter (KDR) and 59.3% (32/54) for flt-4. Significant positive correlations were found between VEGF-C and flt-4, VEGF and KDR, VEGF and flt-1 in tumour tissues. The association between LVD and VEGF-C expression level was especially strong (P< 0.0001, r= 0.63). There were also significant correlations between LVD and flt-4, and VD and VEGF. No correlation, however, was found between LVD and nodal metastasis. VD was a negative prognostic indicator in this study. The associations between VEGFNEGF-C and vessel density suggest that these factors play an important role in angiogenesis and lymphangiogenesis in this tumour, and assessment of vascularity may be a useful prognostic indicator for MPM patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10487612      PMCID: PMC2374345          DOI: 10.1038/sj.bjc.6690650

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  Relation of neovascularisation to metastasis of non-small-cell lung cancer.

Authors:  P Macchiarini; G Fontanini; M J Hardin; F Squartini; C A Angeletti
Journal:  Lancet       Date:  1992-07-18       Impact factor: 79.321

2.  Endothelial cell phenotypic diversity. In situ demonstration of immunologic and enzymatic heterogeneity that correlates with specific morphologic subtypes.

Authors:  R R Turner; J H Beckstead; R A Warnke; G S Wood
Journal:  Am J Clin Pathol       Date:  1987-05       Impact factor: 2.493

3.  Molecular basis of different forms of metachromatic leukodystrophy.

Authors:  A Polten; A L Fluharty; C B Fluharty; J Kappler; K von Figura; V Gieselmann
Journal:  N Engl J Med       Date:  1991-01-03       Impact factor: 91.245

4.  A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases.

Authors:  M Meyer; M Clauss; A Lepple-Wienhues; J Waltenberger; H G Augustin; M Ziche; C Lanz; M Büttner; H J Rziha; C Dehio
Journal:  EMBO J       Date:  1999-01-15       Impact factor: 11.598

5.  Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder.

Authors:  G W Chodak; C Haudenschild; R F Gittes; J Folkman
Journal:  Ann Surg       Date:  1980-12       Impact factor: 12.969

6.  Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.

Authors:  A Kaipainen; J Korhonen; T Mustonen; V W van Hinsbergh; G H Fang; D Dumont; M Breitman; K Alitalo
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

7.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.

Authors:  Y Takahashi; Y Kitadai; C D Bucana; K R Cleary; L M Ellis
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

8.  Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors.

Authors:  K Samoto; K Ikezaki; M Ono; T Shono; K Kohno; M Kuwano; M Fukui
Journal:  Cancer Res       Date:  1995-03-01       Impact factor: 12.701

9.  A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.

Authors:  V Joukov; K Pajusola; A Kaipainen; D Chilov; I Lahtinen; E Kukk; O Saksela; N Kalkkinen; K Alitalo
Journal:  EMBO J       Date:  1996-01-15       Impact factor: 11.598

10.  Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer.

Authors:  M Toi; S Hoshina; T Takayanagi; T Tominaga
Journal:  Jpn J Cancer Res       Date:  1994-10
View more
  78 in total

1.  Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems.

Authors:  J G Edwards; K R Abrams; J N Leverment; T J Spyt; D A Waller; K J O'Byrne
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

2.  Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.

Authors:  Hedy L Kindler; Theodore G Karrison; David R Gandara; Charles Lu; Lee M Krug; James P Stevenson; Pasi A Jänne; David I Quinn; Marianna N Koczywas; Julie R Brahmer; Kathy S Albain; David A Taber; Samuel G Armato; Nicholas J Vogelzang; Helen X Chen; Walter M Stadler; Everett E Vokes
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

Review 3.  Hypoxic tumor microenvironment: Implications for cancer therapy.

Authors:  Sukanya Roy; Subhashree Kumaravel; Ankith Sharma; Camille L Duran; Kayla J Bayless; Sanjukta Chakraborty
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-27

Review 4.  Novel targeted therapies and vaccination strategies for mesothelioma.

Authors:  Mamta Bagia; Anna K Nowak
Journal:  Curr Treat Options Oncol       Date:  2011-06

5.  Biomarkers and prognostic factors for mesothelioma.

Authors:  Harvey I Pass
Journal:  Ann Cardiothorac Surg       Date:  2012-11

6.  Expression of vascular endothelial growth factor-C and angiogenesis in esophageal squamous cell carcinoma.

Authors:  Ming-Xing Ding; Xing-Qiu Lin; Xiao-Yan Fu; Ning Zhang; Ji-Cheng Li
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

7.  Pleural Diseases: Saline Irrigation in Pleural Infection, Epidemiology of Pneumothorax, and Bevacizumab in Mesothelioma.

Authors:  John P Corcoran; Robert J Hallifax; Ioannis Psallidas; Najib M Rahman
Journal:  Am J Respir Crit Care Med       Date:  2017-08-01       Impact factor: 21.405

Review 8.  Tumor stroma as targets for cancer therapy.

Authors:  Jing Zhang; Jinsong Liu
Journal:  Pharmacol Ther       Date:  2012-10-12       Impact factor: 12.310

9.  Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype.

Authors:  Oluf Dimitri Røe; Endre Anderssen; Eli Helge; Caroline Hild Pettersen; Karina Standahl Olsen; Helmut Sandeck; Rune Haaverstad; Steinar Lundgren; Erik Larsson
Journal:  PLoS One       Date:  2009-08-07       Impact factor: 3.240

10.  Lymph node dissection in primary intrahepatic malignant mesothelioma: case report and implications for diagnosis and therapy.

Authors:  Bettina M Buchholz; Ines Gütgemann; Hans-Peter Fischer; Marcus Gorschlüter; Andreas Türler; Jörg C Kalff; Andreas Hirner; Jens Standop
Journal:  Langenbecks Arch Surg       Date:  2009-03-12       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.